Summary
Twenty-four-hour heart rate control by verapamil given as conventional tablets t.d.s., or as a new slow release formulation once daily, has been compared in an open cross-over trial. Eight patients with chronic atrial fibrillation and one with chronic atrial flutter were studied outside hospital.
Trough serum concentration of verapamil did not differ during the two dosage regimens (59 ng/ml — conventional formulation and 49.3 ng/ml — slow release tablet). The average serum concentration of digoxin in the patients was not changed. Compared to the control phase, both dosage regimens significantly and equally reduced individual and average heart rates throughout the entire 24-h period. A positive correlation between the serum concentration of verapamil and the relative increase in average R-R interval was demonstrated.
It is concluded that dosage t.d.s. with conventional tablets of verapamil or once daily with the slow release formulation gave the same antiarrhythmic efficacy over 24 h, and was associated with equal trough serum concentrations of verapamil.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Klein HO, Lang R, Segni ED, Sareli P, David D, Kaplinsky E (1980) Verapamil superior to digoxin in the management of chronic atrial fibrillation? Circulation 62 [Suppl 3]: 307
Lang R, Klein HO, Weiss E, David D, Sareli P, Levy A, Guerrero J, Segni ED, Kaplinsky E (1983) Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 3: 491–499
Lim CK, Rideout JM, Sheldon JWS (1983) Determination of verapamil and norverapamil in serum by high-performance liquid chromatography. J Liquid Chromatogr 6: 877–893
Lagendorf R, Pick A, Katz LN (1965) Ventricular response in atrial fibrillation. Circulation 32: 69–75
Bootsma BK, Hoelen AJ, Strackee J, Meijler F (1970) Analysis of R-R intervals in patients with atrial fibrillation at rest and during exercise. Circulation 41: 783–794
Blumgart H (1924) The reaction to exercise of the heart affected by auricular fibrillation. Heart 11: 49–56
Panidis IP, Morganroth J, Baessler C (1983) Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 52: 1197–1201
Klein HO, Pauzner H, Segni ED, David D, Kaplinsky E (1979) The beneficial effects of verapamil in chronic atrial fibrillation. Arch Int Med 139: 747–749
Klein HO, Kaplinsky E (1982) Verapamil and digoxin: Their respective effects on atrial fibrillation and their interaction. Am J Cardiol 50: 894–902
Goldman S, Probst P, Selzer A, Cohn K (1975) Inefficacy of “therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 35: 661–665
Singh BN, Nademanee K, Baky SH (1983) Calcium antagonists, clinical use in the treatment of arrhythmias. Drugs 25: 125–153
Stern EH, Pitchon R, King BD, Guerrero J, Schneider RR, Weiner I (1982) Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest 81: 3
Lang R, Klein HO, Segni ED, Gefen J, Sareli P, Libhaber C, David D, Weiss E, Guerrero J, Kaplinsky E (1983) Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind cross-over study. Am Heart J 105: 820–825
Andersson P, Bondesson U, Sylvén C (1982) Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. Eur J Clin Pharmacol 23: 49–57
Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J 104: 198
Rietbrock R (1986) Sind “Billigpräparate” immer für therapeutische Zwecke geeignet? Neue Ärztl 128: 1–3
Bühler V, Einig B, Stieren B, Hollmann M (1984) Pharmacokinetics of verapamil sustained release formulation with multiple applications. Naunyn Schmiedebergs Arch Pharmacol 325: 344
Schütz E, Ha HR, Bühler FR, Follath F (1982) Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol 4: S346-S349
Shand DG, Hammil SC, Aanonsen L, Pritchett ELC (1981) Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther 30: 701–703
Freedman SB, Rishmond DR, Ashley JJ, Kelly DT (1981) Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther 30: 644–652
Eichelbaum M, Birkel P, Grube E, Gütgemann U, Somogyi A (1980) Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 58: 919–925
McAllister RG, Kirsten EB (1982) The pharmacology of verapamil i.v. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426
Dominic J, McAllister RG, Kuo CS, Reddy CP, Surawicz B (1979) Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther 26: 710–714
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mølgaard, H., Bjerregaard, P., Jørgensen, H.S. et al. 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. Eur J Clin Pharmacol 33, 447–453 (1987). https://doi.org/10.1007/BF00544233
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544233